Corvus Pharmaceuticals (CRVS) Accumulated Expenses (2015 - 2026)

Corvus Pharmaceuticals' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 64.32% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 64.32% decrease from a year earlier, with the FY2025 full-year figure at $6.5 million, up 74.12% from the prior year.
• Accumulated Expenses slipped to $1.4 million in Q1 2026 per CRVS's latest filing, from $6.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $8.6 million in Q3 2022 and bottomed at $589000.0 in Q1 2024.
• The 5-year median for Accumulated Expenses is $4.2 million (2024), against an average of $3.8 million.
• Across the five-year window, Accumulated Expenses sank 89.52% in 2024 and jumped 557.22% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $1.1 million in 2022, then slumped by 38.54% to $684000.0 in 2023, then soared by 444.59% to $3.7 million in 2024, then surged by 74.12% to $6.5 million in 2025, then sank by 78.71% to $1.4 million in 2026.
• Per Business Quant, the three latest CRVS Accumulated Expenses figures stand at $1.4 million (Q1 2026), $6.5 million (Q4 2025), and $715000.0 (Q3 2025).